Liposomal amphotericin-B (AmBisome) for treatment of cutaneous widespread candidosis in an infant with methylmalonic acidaemia

Eur J Pediatr. 1993 Dec;152(12):981-3. doi: 10.1007/BF01957220.

Abstract

In a 10-week-old infant with vitamin B12-unresponsive methylmalonic acidaemia, cutaneous candidosis (Candida albicans) progressed rapidly despite topical antifungal treatment. After 1 week of intravenous therapy with liposomal amphotericin-B (AmBisome) the dermatitis disappeared completely and blood cultures were sterile. No side-effects were observed. This is one of the first experiences in the treatment of infants with this new antifungal agent.

Publication types

  • Case Reports

MeSH terms

  • Amino Acid Metabolism, Inborn Errors / complications*
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Candidiasis, Cutaneous / drug therapy*
  • Candidiasis, Cutaneous / pathology
  • Humans
  • Infant
  • Infusions, Intravenous
  • Male
  • Methylmalonic Acid / blood*
  • Skin / pathology

Substances

  • liposomal amphotericin B
  • Amphotericin B
  • Methylmalonic Acid